RBBP5 drives cancer stem cell-like characteristics by suppressing the hippo signaling pathway through WNT5A downregulation in breast cancer
- 1Department of HY-KIST Bio-convergence, College of Medicine, Hanyang University, Seoul, Republic of Korea
- 2Department of Pathology, College of Medicine, Hanyang University, Seoul, Republic of Korea
Abstract
Background: Cancer stem cells (CSCs) are a major contributor to breast cancer recurrence and therapeutic resistance. This study investigates the oncogenic role of Retinoblastoma Binding Protein 5 (RBBP5) in driving CSC-like properties in breast cancer.
Methods: Genetic alterations in RBBP5 and their correlation with patient survival were analyzed using multiple breast cancer cohorts, including METABRIC, TCGA, and Kaplan-Meier (KM) plotter datasets. The impact of RBBP5 on CSC-like traits was assessed through tumorsphere formation and ALDEFLUOR assays, and in vivo xenograft models. To elucidate the underlying molecular mechanism, RNA sequencing (RNA-seq) was performed.
Results: Elevated RBBP5 expression was significantly associated with poor prognosis in breast cancer. (METABRIC: OS, p = 0.007; DFS, p = 0.049; TCGA: OS, p < 0.001; KM plotter: RFS, p < 0.001). RBBP5 overexpression enhanced tumorsphere-forming capacity, CSC-like population and tumor-initiating cell frequency. RNA-seq results revealed an enrichment of gene sets associated with negative regulation of cell growth, invasiveness, and stem cell population in RBBP5-knockdown cells. RBBP5 knockdown upregulated WNT5A, a non-canonical Wnt ligand, leading to Hippo pathway activation and subsequent suppression of YAP signaling. Pharmacological inhibition of YAP1 abrogated RBBP5-induced CSC-like properties, while suppression of MST1/2 in RBBP5-knockdown cells restored YAP activity and CSC traits.
Conclusions: These findings indicate that RBBP5 promotes CSC-like properties in breast cancer by repressing WNT5A-mediated Hippo signaling. We suggest RBBP5 as a potential biomarker for poor prognosis and propose that targeting YAP or activating the Hippo pathway could represent a promising therapeutic approach for patients with RBBP5-overexpressing tumors.
Related
- MYH9 confers doxorubicin resistance by stabilizing GRP78 and suppressing the PERK signaling-driven apoptotic pathway in breast cancer
- Sarcandra glabra alleviates intestinal injury via modulating gut microbiota and suppressing the IL-6/SOCS3 signaling pathway
- The resveratrol monomer enhances resistance to bacterial pathogen through the activation of SA-NPR1 signaling pathway in Arabidopsis
- Cardiac Extracellular Matrix derived from younger animals stabilizes macrophage inflammatory polarization through modulation of the interferon signaling pathway
- ADAM8 is associated with asthma exacerbation by promoting lung macrophages apoptosis resistance through PI3K/AKT signaling pathway
BibTeX
@article{moon2026rbbp5,
title = {{RBBP5 drives cancer stem cell-like characteristics by suppressing the hippo signaling pathway through WNT5A downregulation in breast cancer}},
author = {So-Jeong Moon and Young-Hyeon Kye and Gu Kong},
journal = {Cancer Biology \& Therapy},
year = {2026},
month = nov,
doi = {10.1080/15384047.2026.2756150},
url = {https://doi.org/10.1080/15384047.2026.2756150},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - RBBP5 drives cancer stem cell-like characteristics by suppressing the hippo signaling pathway through WNT5A downregulation in breast cancer
AU - So-Jeong Moon
AU - Young-Hyeon Kye
AU - Gu Kong
PY - 2026
DA - 2026/11/07
JO - Cancer Biology & Therapy
DO - 10.1080/15384047.2026.2756150
UR - https://doi.org/10.1080/15384047.2026.2756150
AB - Background: Cancer stem cells (CSCs) are a major contributor to breast cancer recurrence and therapeutic resistance. This study investigates the oncogenic role of Retinoblastoma Binding Protein 5 (RBBP5) in driving CSC-like properties in breast cancer. Methods: Genetic alterations in RBBP5 and their correlation with patient survival were analyzed using multiple breast cancer cohorts, including METABRIC, TCGA, and Kaplan-Meier (KM) plotter datasets. The impact of RBBP5 on CSC-like traits was assessed through tumorsphere formation and ALDEFLUOR assays, and in vivo xenograft models. To elucidate the underlying molecular mechanism, RNA sequencing (RNA-seq) was performed. Results: Elevated RBBP5 expression was significantly associated with poor prognosis in breast cancer. (METABRIC: OS, p = 0.007; DFS, p = 0.049; TCGA: OS, p < 0.001; KM plotter: RFS, p < 0.001). RBBP5 overexpression enhanced tumorsphere-forming capacity, CSC-like population and tumor-initiating cell frequency. RNA-seq results revealed an enrichment of gene sets associated with negative regulation of cell growth, invasiveness, and stem cell population in RBBP5-knockdown cells. RBBP5 knockdown upregulated WNT5A, a non-canonical Wnt ligand, leading to Hippo pathway activation and subsequent suppression of YAP signaling. Pharmacological inhibition of YAP1 abrogated RBBP5-induced CSC-like properties, while suppression of MST1/2 in RBBP5-knockdown cells restored YAP activity and CSC traits. Conclusions: These findings indicate that RBBP5 promotes CSC-like properties in breast cancer by repressing WNT5A-mediated Hippo signaling. We suggest RBBP5 as a potential biomarker for poor prognosis and propose that targeting YAP or activating the Hippo pathway could represent a promising therapeutic approach for patients with RBBP5-overexpressing tumors.
SN - 1538-4047
SN - 1555-8576
ER -